1
|
Epstein AE, Plumb VJ, Henthorn RW, Waldo AL. Phenytoin in the treatment of inducible ventricular tachycardia: results of electrophysiologic testing and long-term follow-up. Pacing Clin Electrophysiol 1987; 10:1049-57. [PMID: 2444929 DOI: 10.1111/j.1540-8159.1987.tb06124.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Phenytoin treatment of inducible ventricular tachyarrhythmias was assessed by serial electrophysiologic studies (EPS) in 64 patients with spontaneous ventricular tachycardia, cardiac arrest, or symptoms compatible with a ventricular tachyarrhythmia. Coronary artery disease was the primary cardiac disease in 75% of the patients. All subjects had either inducible ventricular tachycardia (greater than or equal to 10 repetitive beats) or ventricular fibrillation at electrophysiologic study. Phenytoin was administered intravenously in 38 studies and orally in 31 studies. The mean serum phenytoin level was 19.5 +/- 4.7 mcg/ml. Only seven patients (11%) had a negative electrophysiologic study (less than or equal to 10 repetitive beats) after the administration of phenytoin and were classified as phenytoin responders (group I). The remaining 54 patients (89%) were classified as nonresponders (group II). For the nonresponders, phenytoin increased the cycle length of identical monomorphic ventricular tachycardias from a mean of 31 ms to a mean of 327 ms (p less than 0.001). For the four patients tested receiving both intravenous and oral phenytoin, the intravenous response always predicted the oral response. For the seven patients in whom electrophysiologic study indicated phenytoin efficacy, two are alive and arrhythmia-event free, two had sudden death when the regimen was changed (one case, quinidine added; one case, subtherapeutic serum level), and three died from nonarrhythmic causes. For the 10 patients treated empirically with phenytoin, either alone (seven patients) or in combination with another antiarrhythmic agent (three patients), four died secondary to an arrhythmic event.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A E Epstein
- Department of Medicine, University of Alabama at Birmingham 44106
| | | | | | | |
Collapse
|
2
|
Goodwin JF. Review of hypertrophic cardiomyopathy. ERGEBNISSE DER INNEREN MEDIZIN UND KINDERHEILKUNDE 1987; 55:41-79. [PMID: 3545810 DOI: 10.1007/978-3-642-71052-0_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
3
|
Abstract
This review of practical and theoretical advances in antiarrhythmic drug therapy consists of four parts. Part 1, on clinical applications, compares the approaches to treatment 25 years ago with those of today, examines the current status of antiarrhythmic drugs used 25 years ago, reports on drugs approved for clinical use during the past 25 years, reviews new experimental drugs and suggests an approach to classification of antiarrhythmic drugs. Part 2 summarizes the contributions of cellular electrophysiology to the understanding of drug action, with emphasis on the drug-induced block of the voltage- and time-dependent properties of the rapid sodium channel. The subsequent section contains a brief discussion of the impact made by the new knowledge and the new diagnostic technology on the contemporary practices. The main conclusions are 1) that the more rational approach to treatment has benefited proportionately more patients with supraventricular than with ventricular arrhythmias, and 2) that new advances have made it possible to design successful treatments for certain patients with problems that could not be resolved in the past.
Collapse
|
4
|
Gunnar RM, Lambrew CT, Abrams W, Adolph RJ, Chatterjee K, Cohn JN, Derryberry JS, Horowitz LN, Martin WB, Siciliano EG, Temple R, Tuckman J. Task force IV: pharmacologic interventions. Emergency cardiac care. Am J Cardiol 1982; 50:393-408. [PMID: 6125099 DOI: 10.1016/0002-9149(82)90196-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
5
|
|
6
|
Sami M, Harrison DC, Kraemer H, Houston N, Shimasaki C, DeBusk RF. Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment. Am J Cardiol 1981; 48:147-56. [PMID: 6787910 DOI: 10.1016/0002-9149(81)90584-1] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
7
|
|
8
|
Gábor G. Management of cardiac arrhythmias occurring in myocardial infarction. Pharmacol Ther 1979. [DOI: 10.1016/0163-7258(79)90064-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Koch G, Lindström B. Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity. Eur J Clin Pharmacol 1978; 13:237-40. [PMID: 352705 DOI: 10.1007/bf00716356] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The anti-arrhythmic effect of oral mexiletine on exercise-induced ventricular arrhythmia was studied in a double blind trial of 10 patients suffering from ventricular ectopic beats of different origins. There was a good reproducibility of the amount of ectopic ventricular activity between consecutive exercise tests when no active drug was given. Treatment for 1 week with mexiletine 600 mg daily resulted in a statistically significant reduction in ventricular ectopic beats, particularly during and after exercise; there were virtually no side-effects. The results suggest that mexiletine has considerable potential in the treatment of ventricular arrhythmias.
Collapse
|
10
|
Riker WK, Downes H, Olsen GD, Smith B. Conjugate lateral gaze nystagmus and free phenytoin concentrations in plasma: lack of correlation. Epilepsia 1978; 19:93-8. [PMID: 624271 DOI: 10.1111/j.1528-1157.1978.tb05016.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Electrooculographic recordings during left and right conjugate lateral gaze fixation from 10 degrees to 50 degrees were made in 29 patients being treated with phenytoin. At the time of electrooculographic recordings, venous blood samples were drawn for analysis of total and free phenytoin plasma concentrations. Rhythmic horizontal nystagmus occurred in 7 patients, and only at extreme (40 degrees, 50 degrees) later gaze in 6 of these. Measurable free phenytoin levels in the 29 patients ranged from 0.2 to 3.2 mug/ml, and in the 7 patients with nystagmus were 0.6, 0.8, 1.0, 1.0, 1.7, 1.8, and 3.2 mug/ml. Neither the occurrence of nystagmus nor the degree of lateral gaze at onset could be correlated with free phenytoin concentrations in plasma.
Collapse
|
11
|
Abstract
The patient with recurrent malignant ventricular arrhythmias (ventricular fibrillation or ventricular tachycardia with syncope) presents a complex therapeutic problem. To examine this problem, a study was made of 43 consecutive patients with such arrhythmias (mean age 54 years for the 33 men and 43 years for the 10 women). Arrhythmias were not precipitated by either remediable clinical conditions or acute myocardial infarction. The population was divided into two nonrandomized groups based on the type of therapeutic intervention employed. The 26 patients in Group 1 (20 with ventricular fibrillation, 6 with ventricular tachycardia) were subjected to a systematic attempt to select two independently effective antiarrhythmic drugs. Acute drug testing was followed by drug usage over 48 to 72 hours with drug efficacy determined with use of ambulatory monitoring and exercise stress. The 17 patients in Group 2 (10 with ventricular fibrillation, 7 with ventricular tachycardia) received standard antiarrhythmic therapy based on clinical factors and "therapeutic" blood drug concentrations. Twenty-four of 26 patients in Group 1 (92 percent) demonstrated control of arrhythmias and are alive at a mean follow-up period of 17 months. Of 121 drug tests, 47 (39 percent) were effective, 58 (48 percent) were ineffective and 16 (13 percent) provoked major adverse effects. The most effective combination of drugs involved a beta adrenergic blocking agent, a cardiac glycoside and quinidine. Ten of 17 patients in Group 2 (59 percent) have died after a mean follow-up period of 14.8 months. Elements of a successful management program are outlined.
Collapse
|
12
|
Schmidt D, Vogel A. [Plasma concentrations after injection or infusion of phenytoin (author's transl)]. KLINISCHE WOCHENSCHRIFT 1977; 55:219-23. [PMID: 846182 DOI: 10.1007/bf01487714] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Intravenous injection of 3 mg/kg phenytoin produced plasma concentrations of 4.2 mug/ml in five volunteers, which were below the concentration of 10-20 mjg/ml necessary for effective antiarrhythmic and antiepileptic treatment. Intravenous injection of 250 mg phenytoin followed by infusion of 750 mg phenytoin in a mean dosage of 1.7 mg/kg x h in nine patients with epilepsy produced plasma concentrations of 10.2 resp. 15.1 mug/ml after 4 resp. 8h. An oral maintenance therapy of 5-6 mg/kg is suggested. Therapeutic plasma concentrations were rapidly reached with this regimen.
Collapse
|
13
|
Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lázzari JO, Elizari MV. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976; 38:934-44. [PMID: 793369 DOI: 10.1016/0002-9149(76)90807-9] [Citation(s) in RCA: 413] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Amiodarone, administered orally in doses of 200 to 600 mg/day, was remarkably effective in the treatment and prevention of a wide variety of atrial and ventricular arrhythmias. Total suppression and control was provided in 98 (92.4 percent) of 106 patients with supraventricular arrhythmias and in 119 (82 percent) of 145 patients with ventricular arrhythmias. The rates of total control of the arrhythmia were: 96.6 percent in 30 patients with recurrent atrial flutter or fibrillation, 96.6 percent in 59 patients with repetitive supraventricular tachycardia, 100 percent in 27 patients with Wolff-Parkinson-White syndrome and 77.2 percent in 44 patients with recurrent ventricular tachycardia unsuccessfully treated with other drugs. Excellent results were obtained in 6 to 8 patients with repetitive ventricular tachycardia and ventricular fibrillation related to postinfarction ventricular aneurysm and in 12 of 14 patients with ventricular extrasystoles and ventricular tachycardia related to Chagasic myocarditis. Amiodarone proved safe in patients with severe congestive heart failure and severe myocardial damage. Its clinical efficacy was related to its electrophysiologic properties and to two unique properties: its wide safety margin and its cumulative effect. The latter liberates patients from a rigid hourly schedule and provides for continuous antiarrhythmic control, days and even weeks after treatment is discontinued.
Collapse
|
14
|
Burton JR, Mathew MT, Armstrong PW. Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics. Am J Med 1976; 61:215-20. [PMID: 952294 DOI: 10.1016/0002-9343(76)90172-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Controversy exists regarding the relative safety of intravenously administered lidocaine and procainamide to patients with acutely impaired hemodynamics. Accordingly, their effects were studied in 15 such patients, 14 with acute myocardial infarction and one with cardiomyopathy and severe congestive heart failure. All had elevated levels of pulmonary capillary wedge pressure (greater than 15 mm Hg) and/or low cardiac index (less than 2.5 liters/min/m2). Patients were given lidocaine, a 100 mg bolus followed by a 3 mg/min infusion and, after at least a 30 minute recovery period, procainamide, a 100 mg bolus over 2 minutes followed by a 20 mg/min infusion for 20 to 25 minutes. Hemodynamic measurements were compared early and late in the infusion of each drug. Small, clinically insignificant differences were observed in the hemodynamic responses to the drugs, and no clinically significant deterioration occurred with either. Conventional therapeutic doses of intravenous procainamide can be administered by this regimen, to patients with acute myocardial infarction complicated by cardiac failure or low cardiac output, without producing deleterious hemodynamic effects.
Collapse
|
15
|
Abstract
Twenty-four patients with ventricular arrhythmias were treated with oral mexiletine for periods of from one to 16 months (total 10.4 patient-years). In 19 patients arrhythmias were satisfactorily controlled and plasma levels previously shown to be within the therapeutic range were maintained on an 8 hourly regimen. The drug was well tolerated in most patients and regular hematological and biochemical screening revealed no problems of toxicity.
Collapse
|
16
|
Abstract
To treat patients with ventricular arrhythmias properly, one must characterize the arrhythmia, define the underlying heart disease and look for and treat reversible causes. When arrhythmias are suitable for pharmacologic suppression, it is necessary to predefine therapeutic goals, then carefully document that the drug accomplishes these goals. Knowledge of a drug's metabolism, excretion, active metabolites and plasma protein binding is often required for full understanding of its clinical effect. Pharmacokinetic principles require that antiarrhythmic drugs be given on a rigid schedule and that plasma drug levels be frequently determined. Use of compartment models and the principle of superposition can enable one to achieve and maintain therapeutic drug concentrations while avoiding toxic side effects. The drugs commonly used to treat arrhythmias, lidocaine, propranolol, procainamide, diphenylhydantoin and quinidine, as well as some newer agents, have specific pharmacokinetics and toxic effects that must be understood.
Collapse
|
17
|
Wit AL, Rosen MR, Hoffman BF. Electrophysiology and pharmacology of cardiac arrhythmias. VIII. Cardiac effects of diphenylhydantoin. A. Am Heart J 1975; 90:265-72. [PMID: 1155329 DOI: 10.1016/0002-8703(75)90130-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
18
|
Karlsson E. Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Heart 1975; 37:731-40. [PMID: 1098684 PMCID: PMC482865 DOI: 10.1136/hrt.37.7.731] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The antiarrhythmic effects of procainamide and phenytoin were studied in 81 patients admitted to the coronary care unit at the University Hospital in Linköping because of a suspected or proven diagnosis of acute myocardial infarction, and who developed ventricular arrhyhmias, requiring treatment, during the first 8 hours in hospital. Patients were randomly allocated to a procainamide of phenytoin group. The drugs were given as intravenous and oral loading doses followed by oral maintenance therapy. Plasma levels of the two druge were frequently determined and the electrocardiogram was continuously recorded during the 24-hour trial and analysed minute by minute. A significantly higher frequency of therapeutic failure was found in the phenytoin group (23 of 35 patients)compared to the procainamide group(13 of 39 aptients) during the first 2 hours after initiation of therapy. Four patients in the phenytoin group and 2 in the procainamide group developed symptoms probably caused by the trial drugs, necessitating discontinuation of therapy. The mean plasma levels were usually within the apparent therapeutic range (for phenytoin 40-72 mumol/l (10-18 mug/ml), and for procainamide 17-34 mumol/l (4-8 mug/ml). Seventeen patients (68%) in the phenytoin group and 10 patients (48%) in the procainamide group had plasma concentrations within this range when the therapeutic failure was observed. Nine patients died in hospital but only one of them during the trial. The results of this investigation clearly demonstrate the overall superiority of procainamide over phenytoin as an antiarrhythmic drug in short-term therapy after acute myocardial infarction.
Collapse
|
19
|
|
20
|
|
21
|
|
22
|
Gambetta M, Lipp H. Coronary care. The understanding and treatment of atrial and ventricular dysrhythmias. Med Clin North Am 1973; 57:125-42. [PMID: 4569826 DOI: 10.1016/s0025-7125(16)32307-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
23
|
|